OncoVerity Secures Extended Series A to Advance Cusatuzumab in Newly Diagnosed AML
First patients dosed in OV-AML-1231, a Phase 2 randomized controlled trial of cusatuzumab in newly diagnosed AML November 21, 2024 02:06 PM Eastern Standard Time AURORA, Colo.–(BUSINESS WIRE)–OncoVerity, a pioneer in applying advanced bioinformatics to…